There are currently 1293 clinical trials in Miami, Florida looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Miami, GSK Investigational Site, University of Miami Miller School of Medicine-Sylvester Cancer Center and University of Miami Miller School of Medicine. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
The Rapid Diagnosis of MCI and Depression in Patients Ages 60 and Over
NCT06011681
Recruiting
Mild cognitive impairment (MCI) leading to Alzheimer's disease and related disorders (ADRD) represents a significant health and economic burden of the rapidly expanding senior population. The accurate detection and diagnosis of MCI and its common comorbidity, late-life depression (LLD), is essential for prolonging patient quality of life and developing advancements in research and treatment options. The purpose of the proposed program is to refine Miro Health's A.I. to accurately detect, differe... Read More
Gender:
ALL
Ages:
60 years and above
Trial Updated:
01/18/2024
Locations: Miro Health, Miami, Florida
Conditions: Depression, Mild Cognitive Impairment
Register for Updates
Ablation With Confirmation of Colorectal Liver Metastases (ACCLAIM)
NCT05265169
Recruiting
To demonstrate that microwave ablation (MWA) of up to 3 hepatic metastases, each with a maximum diameter of ≤ 2.5 cm will result in a 2-year local progression free survival of at least 90%. This is a standard of care (SOC) study.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/16/2024
Locations: Miami Cancer Institute, Miami, Florida
Conditions: Colorectal Liver Metastases
Register for Updates
Prospective Database Registry Study of Scoliosis in Children With Cerebral Palsy
NCT00680264
Recruiting
The purpose of this study is to determine the radiographic and clinical outcomes of Scoliosis surgical and non-operative treatment in patients with Cerebral Palsy.
Gender:
ALL
Ages:
Between 8 years and 21 years
Trial Updated:
11/20/2023
Locations: Miami Children's Hospital, Miami, Florida
Conditions: Cerebral Palsy, Scoliosis
Register for Updates
A Phase II Study of Nivolumab + Ipilimumab in Advanced HCC Patients Who Have Progressed on First Line Atezolizumab + Bevacizumab
NCT05199285
Recruiting
This phase II trial tests whether nivolumab and ipilimumab works to shrink tumors in patients with liver cancer that has spread to nearby tissue or lymph nodes (locally advanced), has spread to other places in the body (metastatic), or cannot be removed by surgery (unresectable). Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Nivolumab and ipilim... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/13/2023
Locations: University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida
Conditions: BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma, Locally Advanced Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8, Stage IIIA Hepatocellular Carcinoma AJCC v8, Stage IIIB Hepatocellular Carcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8, Stage IVA Hepatocellular Carcinoma AJCC v8, Stage IVB Hepatocellular Carcinoma AJCC v8, Unresectable Hepatocellular Carcinoma
Register for Updates
LUT014 for the Reduction of Dose-Limiting Acneiform Lesions Associated With EGFRI Treatment of mCRC
NCT04759664
Recruiting
The study evaluates the efficacy and safety of two strengths of LUT014 Gel topically applied once a day for 4 weeks, compared to placebo, in metastatic colorectal cancer (mCRC) patients who developed Grade 2 or non-infected Grade 3 EGFRI induced acneiform lesions
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/05/2023
Locations: Miami Dermatology & Laser Research, Miami, Florida +1 locations
Conditions: EGFRI Induced Acneiform Lesions
Register for Updates
CAN-Stim Compared to SNS in Treatment of Urinary Urgency Incontinence With Wireless Neuromodulation Technology
NCT02577302
Recruiting
This is a prospective, randomized, controlled, multi-center, study in which 150 evaluable subjects will be randomized 1:1 to receive either a Protect CAN-Stim or SNS InterStim® system. Subjects from both groups will immediately start with therapy. The primary endpoint is a ≥ 50% reduction in number of incontinence episodes associated with urgency at the 3-month visit, with additional measurements assessed at 14 days, 1, 6, 9 and 12-months.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/03/2023
Locations: Baptist Health Miami Cancer Institute, Miami, Florida
Conditions: Urinary Incontinence, Urge
Register for Updates
The Efficacy and Safety of Bonjesta® for Nausea and Vomiting of Pregnancy in Pregnant Adolescents
NCT05289557
Recruiting
The primary objective of this study is to compare the efficacy of Bonjesta for the treatment of nausea and vomiting of pregnancy (NVP) in pregnant adolescents aged 12 to 17 years with placebo. The secondary objective of this study is to compare the safety of Bonjesta in pregnant adolescents aged 12 to 17 years with placebo.
Gender:
FEMALE
Ages:
Between 12 years and 17 years
Trial Updated:
09/08/2023
Locations: New Horizon Research Center, Miami, Florida
Conditions: Morning Sickness
Register for Updates
A Phase 3 Study to Investigate the Efficacy and Safety of SHR0302 With Moderately to Severely Active Ulcerative Colitis
NCT05181137
Recruiting
This is a randomized, double-blind, placebo-controlled, multicenter Phase 3 study that will enroll approximately 368 subjects aged 18 to 75 years old with Moderately to Severely Active Ulcerative Colitis.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
09/01/2023
Locations: Dade Research Center, Miami, Florida
Conditions: Ulcerative Colitis
Register for Updates
Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti Cancer Treatments
NCT04056247
Recruiting
This study will develop an algorithm of identifying patients with stage IV NSCLC and Melanoma who could benefit from cancer treatment they receive.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/25/2023
Locations: University of Miami, Miami, Florida
Conditions: Stage IV Non-small Cell Lung Cancer, Stage IV Small Cell Lung Cancer, Stage III Malignant Melanoma, Stage IV Malignant Melanoma
Register for Updates
The Use of Electromagnetic Field (EMF) Treatment in Chronic Spinal Cord Injury (SCI) Patients
NCT04050696
Recruiting
The purpose of this study is to further establish safety and efficacy of the BQ EMF treatment of chronic SCI subjects who demonstrate stability in The Graded and Redefined Assessment of Strength, Sensibility and Prehension (GRASSP) strength score following a one-month physical therapy run-in period.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
08/21/2023
Locations: The Miami Project to Cure Paralysis, Miami, Florida
Conditions: Incomplete Spinal Cord Injury
Register for Updates
An Open-label, Single-dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Brodalumab in Pediatric Subjects
NCT03240809
Recruiting
An Open-label, Single-dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Brodalumab in Pediatric Subjects
Gender:
ALL
Ages:
Between 6 years and 18 years
Trial Updated:
08/09/2023
Locations: Bausch Site 002, Miami, Florida +1 locations
Conditions: Psoriasis
Register for Updates
The Effect of Guided Care With Vectra Compared to Treatment as Usual in Patients With Rheumatoid Arthritis
NCT03631225
Recruiting
The goal of treating patients diagnosed with rheumatoid arthritis (RA) is to achieve remission or low disease activity and thereby prevent joint damage, loss of physical function, and disability. Optimal management requires regular assessment of disease activity, with treatment changes made as needed for optimal efficacy. Vectra is a blood serum test that looks at 12 biomarkers and produces a score on a scale of 1 to 100. The Vectra score has been shown to be the strongest predictor of risk for... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/07/2023
Locations: Artemisa Analytics, Miami, Florida
Conditions: Rheumatoid Arthritis (RA)
Register for Updates